Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...
The investigational PAM inhibitor extends progression-free survival from 5 to 7 months in patients with advanced, PIK3CA wild ...
Glucagon-like peptide 1 receptor agonists (GLP-1RA) have made waves as treatments for obesity and type 2 diabetes, but a new report suggests they might also have clinical benefits for certain patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback